Virus clearance methods applied in bioprocessing operations: an overview of selected inactivation and removal methods

Viral safety is an integral component of the process design for products derived from biological sources. While each step may contribute to viral safety, specific steps to remove and or inactivate potential viral contamination should be incorporated. The purpose of this article is to provide a brief overview to some of these specific viral clearance steps and how they may be applied in a manufacturing process. Each of these methodologies have a proven ability to remove or inactivate viruses, however selection and implementation of these methods is dependent on a variety of factors beyond the potential reduction achieved. The application of a selected method should be appropriately investigated and characterized before the implementation into the manufacturing process and subsequent viral safety assessment.

[1]  S. Wickramasinghe,et al.  Tangential flow filtration for virus purification , 2008 .

[2]  R. Nims,et al.  Gamma irradiation of animal sera for inactivation of viruses and mollicutes--a review. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[3]  Hazel Aranha,et al.  Virus Retentive Filters , 2010 .

[4]  B. Horowitz,et al.  Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD‐Plasma , 1998, Vox sanguinis.

[5]  Griffin,et al.  Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research. , 1997, Journal of immunotherapy.

[6]  Revised VIRUS VALIDATION STUDIES : THE DESIGN , CONTRIBUTION AND INTERPRETATION OF STUDIES VALIDATING THE INACTIVATION AND REMOVAL OF VIRUSES , 1996 .

[7]  M. Moore Inactivation of enveloped and non-enveloped viruses on seeded human tissues by gamma irradiation , 2011, Cell and Tissue Banking.

[8]  Kurt Brorson,et al.  Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. , 2003, Biotechnology and bioengineering.

[9]  Ich Topic Q5A GUIDANCE FOR INDUSTRY Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin , 2001 .

[10]  In-Seop Kim,et al.  Evaluation of Viral Inactivation Efficacy of a Continuous Flow Ultraviolet-C Reactor (UVivatec) , 2009 .

[11]  Dayue Chen,et al.  Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[12]  K. Yamaguchi,et al.  Effects of varying virus‐spiking conditions on a virus‐removal filter Planova™ 20N in a virus validation study of antibody solutions , 2011, Biotechnology progress.

[13]  A. Prince,et al.  STERILISATION OF HEPATITIS AND HTLV-III VIRUSES BY EXPOSURE TO TRI(n-BUTYL)PHOSPHATE AND SODIUM CHOLATE , 1986, The Lancet.

[14]  P. Hellstern,et al.  The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma , 2011, Transfusion Medicine and Hemotherapy.